Daratumumab Monotherapy Shows Clinical Benefit for Early Intervention for Patients with High-Risk Smoldering Multiple Myeloma

There is an unmet need for treatment of patients with high-risk smoldering multiple myeloma. Maybe the Aquila trial can give a breakthrough. At ASH 2024, Meletios-Athanasios Dimopoulos presented the results showing a clinically meaningful and significant benefit in preventing or delaying progression to active multiple myeloma compared with active monitoring in patients with high-risk smoldering multiple myeloma.